Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

NCT07695701 is registered in ClinicalTrials.gov with Eidos Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT07695701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07695701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Phase
Phase 4
Overall status
Recruiting
Start date
July 31, 2026
Completion date
November 30, 2030
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid cardiomyopathy, amyloidosis, transthyretin amyloidosis, transthyretin amyloidosis cardiomyopathy (attr-cm)